Rituxan

Latest stories

8d
The Economic Times
Novartis aims to nearly triple biosimilar drugs on market by 2020of AbbVie's $13 billion blockbuster Humira, Amgen's Enbrel and Neulasta, Johns
Novartis aims to nearly triple biosimilar drugs on market by 2020
The Economic Times / Posted 8 days ago
of AbbVie's $13 billion blockbuster Humira, Amgen's Enbrel and Neulasta, Johnson & Johnson's Remicade and Roche's Rituxan would arrive in pharmacies over the next four years, barring stumbles. The five original drugs booked $44 billion in... Read more
2 related stories
8d
The Financial Express
Switzerland Novartis aims to nearly triple biosimilar drugs on market by 2020versions of AbbVie’s $13 billion blockbuster Humira, Amgen’s Enbrel and Neulast
Switzerland Novartis aims to nearly triple biosimilar drugs on market by 2020
The Financial Express / Posted 8 days ago
versions of AbbVie’s $13 billion blockbuster Humira, Amgen’s Enbrel and Neulasta, Johnson & Johnson’s Remicade and Roche’s Rituxan would arrive in pharmacies over the next four years, barring stumbles. The five original drugs booked $44 billion in... Read more
2 related stories
8d
Channel NewsAsia
Novartis aims to nearly triple biosimilar drugs on market by 2020of AbbVie's US$13 billion blockbuster Humira, Amgen's Enbrel and Neulasta, John
Novartis aims to nearly triple biosimilar drugs on market by 2020
Channel NewsAsia / Posted 8 days ago
of AbbVie's US$13 billion blockbuster Humira, Amgen's Enbrel and Neulasta, Johnson & Johnson's Remicade and Roche's Rituxan would arrive in pharmacies over the next four years, barring stumbles. The five original drugs booked US$44 billion... Read more
2 related stories
8d
FOX Business
1 Stock to Invest in Big Pharmajust one Big Pharma stock, I'd go withRoche in a heartbeat. I'll start with the
1 Stock to Invest in Big Pharma
FOX Business / Posted 8 days ago
just one Big Pharma stock, I'd go withRoche in a heartbeat. I'll start with the bad news: Its aging cancer therapies, Rituxan and Herceptin, first earned FDA approval in 1997 and 1998, respectively. Combined, these two drugs were responsible... Read more
8d
FOX Business
1 Stock to Invest in Big Pharmajust one Big Pharma stock, I'd go withRoche in a heartbeat. I'll start with the
1 Stock to Invest in Big Pharma
FOX Business / Posted 8 days ago
just one Big Pharma stock, I'd go withRoche in a heartbeat. I'll start with the bad news: Its aging cancer therapies, Rituxan and Herceptin, first earned FDA approval in 1997 and 1998, respectively. Combined, these two drugs were responsible... Read more
11d
Morningstar
Biogen Remains UndervaluedMultiyear Dominance Biogen’s strategy has its roots in the 2003 merger of Bioge
Biogen Remains Undervalued
Morningstar / Posted 11 days ago
Multiyear Dominance Biogen’s strategy has its roots in the 2003 merger of Biogen (MS drug Avonex) and Idec (cancer drug Rituxan). Rituxan’s market penetration is already high, and patents in the United States, where Biogen derives its profit... Read more
14d
Business Wire
Therapeutic Antibody Reports Bundle 2016: Key Report on ADCs, Bispecifics, Biosimilars & Biosuperiorsfirst wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avas
Therapeutic Antibody Reports Bundle 2016: Key Report on ADCs, Bispecifics, Biosimilars & Biosuperiors
Business Wire / Posted 14 days ago
first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia,... Read more
21d
Business Wire
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Updatefirst wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avas
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
Business Wire / Posted 21 days ago
first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia,... Read more
21d
Business Wire
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies Market Report 2016of CD20 antibodies. Key Topics Covered: 1. 2015 Sales of Anti-CD20 Antibodies
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies Market Report 2016
Business Wire / Posted 21 days ago
of CD20 antibodies. Key Topics Covered: 1. 2015 Sales of Anti-CD20 Antibodies 2. Originator Anti-CD20 Antibodies - Rituxan/MabThera Approved Indications & Pipeline - Gazyva Approved Indications & Pipeline - Arzerra Approved Indications... Read more
21d
Hawaii News Now
Cancer drugs less affordable in poor nations than USfor differences in living standards in each country. The patented, or brand-na
Cancer drugs less affordable in poor nations than US
Hawaii News Now / Posted 21 days ago
for differences in living standards in each country. The patented, or brand-name, drugs included Avastin, Herceptin and Rituxan. Patents give a monopoly for a decade or longer. For the eight patented drugs, the median monthly price -the... Read more
15 related stories
21d
Your Hometown Lima Stations
Cancer drugs less affordable in poor nations than USfor differences in living standards in each country. The patented, or brand-na
Cancer drugs less affordable in poor nations than US
Your Hometown Lima Stations / Posted 21 days ago
for differences in living standards in each country. The patented, or brand-name, drugs included Avastin, Herceptin and Rituxan. Patents give a monopoly for a decade or longer. For the eight patented drugs, the median monthly price -the... Read more
15 related stories
21d
Everett Herald
Study: Cancer drugs less affordable in poor nations than U.S.for differences in living standards in each country.The patented, or brand-name
Study: Cancer drugs less affordable in poor nations than U.S.
Everett Herald / Posted 21 days ago
for differences in living standards in each country.The patented, or brand-name, drugs included Avastin, Herceptin and Rituxan. Patents give a monopoly for a decade or longer.For the eight patented drugs, the median monthly price �the midpoint,... Read more
15 related stories
21d
Salon.com
Cancer drugs less affordable in poor nations than USliving standards in each country. You Might Also Like The patented, or brand-
Cancer drugs less affordable in poor nations than US
Salon.com / Posted 21 days ago
living standards in each country. You Might Also Like The patented, or brand-name, drugs included Avastin, Herceptin and Rituxan. Patents give a monopoly for a decade or longer. For the eight patented drugs, the median monthly price —the... Read more
15 related stories
24d
FOX Business
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)versions of blockbuster treatment Humira (the highest-grossing drug in the worl
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)
FOX Business / Posted 24 days ago
versions of blockbuster treatment Humira (the highest-grossing drug in the world last year) and cancer treatments Avastin, Rituxan, and Herceptin.Changing lanes Biogen is mostly known for its massive multiple-sclerosis drug franchise, which... Read more
3 related stories
24d
FOX Business
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)versions of blockbuster treatment Humira (the highest-grossing drug in the worl
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)
FOX Business / Posted 24 days ago
versions of blockbuster treatment Humira (the highest-grossing drug in the world last year) and cancer treatments Avastin, Rituxan, and Herceptin.Changing lanes Biogen is mostly known for its massive multiple-sclerosis drug franchise, which... Read more
3 related stories
25d
FOX Business
13-Point Checklist for Buying a Biotech Stockpatient investors. We've seen this story before: Over 20 years ago,Biogenlet R
13-Point Checklist for Buying a Biotech Stock
FOX Business / Posted 25 days ago
patient investors. We've seen this story before: Over 20 years ago,Biogenlet Roche help it develop what eventually became Rituxan and Gazyva. Last year Biogen's share ofRituxan's and Gazyva's operating profits totaled $1.3 billion, and Biogen has... Read more
25d
FOX Business
13-Point Checklist for Buying a Biotech Stockpatient investors. We've seen this story before: Over 20 years ago,Biogenlet R
13-Point Checklist for Buying a Biotech Stock
FOX Business / Posted 25 days ago
patient investors. We've seen this story before: Over 20 years ago,Biogenlet Roche help it develop what eventually became Rituxan and Gazyva. Last year Biogen's share ofRituxan's and Gazyva's operating profits totaled $1.3 billion, and Biogen has... Read more
28d
Channel NewsAsia
Roche and Novartis face off in biosimilar drug battleis considering selling its US$14 billion stake in cross-town rival Roche. With
Roche and Novartis face off in biosimilar drug battle
Channel NewsAsia / Posted 28 days ago
is considering selling its US$14 billion stake in cross-town rival Roche. With a copycat of Roche's blood cancer drug Rituxan pending European approval, Novartis aims to muscle in on a share of sales that last year hit 7 billion Swiss francs... Read more
29d
FOX Business
These 5 Big Pharma Stocks Are Ridiculously Cheapthis big pharma stock boasts a hefty 3.6% dividend yield.Roche is firing on all
These 5 Big Pharma Stocks Are Ridiculously Cheap
FOX Business / Posted 29 days ago
this big pharma stock boasts a hefty 3.6% dividend yield.Roche is firing on all cylinders Roche's top selling drugs Rituxan and Herceptin are widely expected to face pricing pressure from biosimilar competition in the years ahead. In the... Read more
29d
FOX Business
These 5 Big Pharma Stocks Are Ridiculously Cheapthis big pharma stock boasts a hefty 3.6% dividend yield.Roche is firing on all
These 5 Big Pharma Stocks Are Ridiculously Cheap
FOX Business / Posted 29 days ago
this big pharma stock boasts a hefty 3.6% dividend yield.Roche is firing on all cylinders Roche's top selling drugs Rituxan and Herceptin are widely expected to face pricing pressure from biosimilar competition in the years ahead. In the... Read more
m
FOX Business
Regeneron Pharmaceuticals, Inc. vs. Rochepressure from biosimilars -- generic forms of complex biologic drugs -- in the
Regeneron Pharmaceuticals, Inc. vs. Roche
FOX Business / Posted 1 months ago
pressure from biosimilars -- generic forms of complex biologic drugs -- in the near future. Sales of cancer therapies Rituxan and Herceptin are still growing by single digits despite first earning FDA approval in 1997 and 1998, respectively.... Read more
m
FOX Business
Regeneron Pharmaceuticals, Inc. vs. Rochepressure from biosimilars -- generic forms of complex biologic drugs -- in the
Regeneron Pharmaceuticals, Inc. vs. Roche
FOX Business / Posted 1 months ago
pressure from biosimilars -- generic forms of complex biologic drugs -- in the near future. Sales of cancer therapies Rituxan and Herceptin are still growing by single digits despite first earning FDA approval in 1997 and 1998, respectively.... Read more
m
Channel NewsAsia
Roche boosted by trial success with blood cancer drugcompany fights the threat of biosimilar competition. Roche said Gazyva proved
Roche boosted by trial success with blood cancer drug
Channel NewsAsia / Posted 1 months ago
company fights the threat of biosimilar competition. Roche said Gazyva proved significantly better than its older drug Rituxan at delaying the progression of disease in people with previously untreated follicular lymphoma. Clinical trials with... Read more
m
Channel NewsAsia
Roche announces positive results for Gazyva in phase III studyZURICH: Roche Holding AG said on Friday its drug Gazyva showed superior progres
Roche announces positive results for Gazyva in phase III study
Channel NewsAsia / Posted 1 months ago
ZURICH: Roche Holding AG said on Friday its drug Gazyva showed superior progression-free survival compared to Mabthera/Rituxan in people with previously untreated follicular lymphoma in the pivotal phase III Gallium study that met is primary endpoint... Read more
m
Business Wire
Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphomasafety of Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine)
Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma
Business Wire / Posted 1 months ago
safety of Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone. Results from a pre-planned interim analysis showed that... Read more

People in this news